Year |
Citation |
Score |
2021 |
Buchman TG, Simpson SQ, Sciarretta KL, Finne KP, Sowers N, Collier M, Chavan S, Do R, Lin C, Oke I, Rhodes KE, Santhosh A, Sandhu AT, Chu S, Patel SA, ... ... Bright RA, et al. Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries. Vaccine. PMID 34836659 DOI: 10.1016/j.vaccine.2021.11.016 |
0.475 |
|
2021 |
Oshansky CM, King J, Lu D, Zhou J, Pavetto C, Horwith G, Biscardi K, Nguyen B, Treanor JJ, Chen LM, Jepson B, Bright RA, Johnson RA, Cioce V, et al. Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults. Npj Vaccines. 6: 41. PMID 33741987 DOI: 10.1038/s41541-021-00287-7 |
0.64 |
|
2019 |
King JC, Beigel JH, Ison MG, Rothman RE, Uyeki TM, Walker RE, Neaton JD, Tegeris JS, Zhou JA, Armstrong KL, Carter W, Miele PS, Willis MS, Dugas AF, Tracy LA, ... ... Bright RA, et al. Clinical Development of Therapeutic Agents for Hospitalized Patients With Influenza: Challenges and Innovations. Open Forum Infectious Diseases. 6: ofz137. PMID 31037242 DOI: 10.1093/Ofid/Ofz137 |
0.536 |
|
2018 |
Oshansky CM, Zhou J, Gao Y, Schweinle JE, Biscardi K, DeBeauchamp J, Pavetto C, Wollish A, Webby RJ, Cioce V, Donis RO, Bright RA. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Vaccine. PMID 30553570 DOI: 10.1016/J.Vaccine.2018.11.069 |
0.584 |
|
2013 |
Gessner BD, Brooks WA, Neuzil KM, Vernet G, Bright RA, Tam JS, Bresee J, Monto AS. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine. 31: 3222-8. PMID 23707161 DOI: 10.1016/J.Vaccine.2013.05.017 |
0.592 |
|
2013 |
Wathen MW, Barro M, Bright RA. Antivirals in seasonal and pandemic influenza--future perspectives. Influenza and Other Respiratory Viruses. 7: 76-80. PMID 23279900 DOI: 10.1111/Irv.12049 |
0.579 |
|
2012 |
Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Review of Vaccines. 11: 939-47. PMID 23002975 DOI: 10.1586/Erv.12.76 |
0.645 |
|
2011 |
Perdue ML, Bright RA. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine. 29: A48-50. PMID 21684430 DOI: 10.1016/J.Vaccine.2011.02.080 |
0.558 |
|
2010 |
Mochalova L, Bright R, Xu X, Korchagina E, Chinarev A, Bovin N, Klimov A. Shift in oligosaccharide specificities of hemagglutinin and neuraminidase of influenza B viruses resistant to neuraminidase inhibitors. Glycoconjugate Journal. 27: 321-7. PMID 20195900 DOI: 10.1007/S10719-010-9280-7 |
0.557 |
|
2009 |
Bright RA, Neuzil KM, Pervikov Y, Palkonyay L. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine. 27: 6366-9. PMID 19840675 DOI: 10.1016/J.Vaccine.2009.02.084 |
0.581 |
|
2009 |
Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Current Topics in Microbiology and Immunology. 333: 269-89. PMID 19768411 DOI: 10.1007/978-3-540-92165-3_14 |
0.666 |
|
2009 |
Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. The Journal of Infectious Diseases. 200: 835-7. PMID 19673653 DOI: 10.1086/605507 |
0.628 |
|
2009 |
Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. Plos One. 4: e6032. PMID 19554101 DOI: 10.1371/Journal.Pone.0006032 |
0.682 |
|
2009 |
Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrobial Agents and Chemotherapy. 53: 1039-47. PMID 19124660 DOI: 10.1128/Aac.01446-08 |
0.572 |
|
2008 |
Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, Zeng H, Tumpey TM, Katz JM. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunological Reviews. 225: 68-84. PMID 18837776 DOI: 10.1111/J.1600-065X.2008.00690.X |
0.665 |
|
2008 |
Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 26: 5393-9. PMID 18706956 DOI: 10.1016/J.Vaccine.2008.07.084 |
0.63 |
|
2008 |
Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy. 52: 3284-92. PMID 18625765 DOI: 10.1128/Aac.00555-08 |
0.636 |
|
2008 |
Rahman M, Bright RA, Kieke BA, Donahue JG, Greenlee RT, Vandermause M, Balish A, Foust A, Cox NJ, Klimov AI, Shay DK, Belongia EA. Adamantane-resistant influenza infection during the 2004-05 season. Emerging Infectious Diseases. 14: 173-6. PMID 18258102 DOI: 10.3201/Eid1401.070460 |
0.564 |
|
2008 |
Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. Plos One. 3: e1501. PMID 18231588 DOI: 10.1371/Journal.Pone.0001501 |
0.68 |
|
2007 |
Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. The Journal of Infectious Diseases. 196: 249-57. PMID 17570112 DOI: 10.1086/518936 |
0.618 |
|
2007 |
Chen H, Bright RA, Subbarao K, Smith C, Cox NJ, Katz JM, Matsuoka Y. Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Research. 128: 159-63. PMID 17521765 DOI: 10.1016/J.Virusres.2007.04.017 |
0.707 |
|
2007 |
Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 25: 4283-90. PMID 17403562 DOI: 10.1016/j.vaccine.2007.02.059 |
0.756 |
|
2007 |
Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 25: 3871-8. PMID 17337102 DOI: 10.1016/J.Vaccine.2007.01.106 |
0.656 |
|
2006 |
Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (London, England). 367: 475-81. PMID 16473124 DOI: 10.1016/S0140-6736(06)68076-8 |
0.75 |
|
2006 |
Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. Jama. 295: 891-4. PMID 16456087 DOI: 10.1001/Jama.295.8.Joc60020 |
0.631 |
|
2006 |
Shay DK, Bright RA, Shaw M, Cox NJ, Klimov AI. Shift Shown in Influenza A Adamantane Resistance—Reply Jama. 296: 1585. DOI: 10.1001/Jama.296.13.1586 |
0.688 |
|
2005 |
Aubin JT, Azebi S, Balish A, Banks J, Bhat N, Bright RA, Brown I, Buchy P, Burguiere AM, Chen HI, Cheng P, Cox NJ, Crosier A, Curns A, Cuvelier F, et al. Evolution of H5N1 avian influenza viruses in Asia Emerging Infectious Diseases. 11: 1515-1521. PMID 16318689 |
0.699 |
|
2005 |
Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (London, England). 366: 1175-81. PMID 16198766 DOI: 10.1016/S0140-6736(05)67338-2 |
0.66 |
|
2005 |
Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith C, Hill RC, Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW, Cox NJ, et al. Transmission of equine influenza virus to dogs. Science (New York, N.Y.). 310: 482-5. PMID 16186182 DOI: 10.1126/Science.1117950 |
0.749 |
|
2003 |
Bright RA, Cho DS, Rowe T, Katz JM. Mechanisms of pathogenicity of influenza A (H5N1) viruses in mice. Avian Diseases. 47: 1131-4. PMID 14575128 DOI: 10.1637/0005-2086-47.S3.1131 |
0.742 |
|
2003 |
Rowe T, Cho DS, Bright RA, Zitzow LA, Katz JM. Neurological manifestations of avian influenza viruses in mammals. Avian Diseases. 47: 1122-6. PMID 14575126 DOI: 10.1637/0005-2086-47.S3.1122 |
0.656 |
|
2003 |
Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology. 308: 270-8. PMID 12706077 DOI: 10.1016/S0042-6822(03)00008-4 |
0.72 |
|
2003 |
Mitchell JA, Green TD, Bright RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine. 21: 902-14. PMID 12547601 DOI: 10.1016/S0264-410X(02)00539-X |
0.692 |
|
2000 |
Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge Nature Immunology. 1: 127-131. PMID 11248804 DOI: 10.1038/77802 |
0.474 |
|
Show low-probability matches. |